论文部分内容阅读
[目的]观察血府逐瘀汤联合干扰素治疗慢性乙型肝炎疗效。[方法]使用随机平行对照方法,将75例门诊患者按掷骰子法随机分为两组。普通干扰素(3~5MU),皮下注射,每周3次。对照组35例注射用重组人干扰素α2a,3~5MU/次,3次/周,皮注。治疗组40例血府逐瘀汤(桃仁15g,当归10g,牛膝、红花各8g,川芎、桔梗各6g,赤芍药、柴胡、枳壳、甘草各5g);1剂/d,水煎150mL,早晚口服,服药间隔>8h。西药治疗同对照组。连续治疗6个月为1疗程。观测临床症状、不良反应。治疗1疗程,判定疗效。[结果]治疗组显效24例,有效10例,无效6例,总有效率85.00%。对照组显效14例,有效11例,无效10例,总有效率71.43%。治疗组疗效优于对照组(P<0.05)。HBV-DNA转阴例数治疗组优于对照组(P<0.05)。相关指标两组均有改善(P<0.05),治疗组改善优于对照组(P<0.05)。[结论]血府逐瘀汤联合干扰素治疗慢性乙型肝炎效果显著,值得推广。
[Objective] To observe the curative effect of Xuefuzhuyu Decoction combined with interferon on chronic hepatitis B [Methods] Using randomized parallel control method, 75 outpatients were randomly divided into two groups according to the method of dice. Ordinary interferon (3 ~ 5MU), subcutaneous injection, 3 times a week. Control group of 35 patients injected with recombinant human interferon α2a, 3 ~ 5MU / time, 3 times / week, skin injection. The treatment group 40 cases of Xuefuzhuyu Decoction (peach kernel 15g, Angelica 10g, Achyranthes, safflower each 8g, Chuanxiong, Campanulaceae 6g, red peony root, Bupleurum, Citrus aurantium, licorice each 5g); 1 / d, water Fried 150mL, sooner or later oral administration, medication interval> 8h. Western medicine treatment with the control group. Continuous treatment of 6 months for a course of treatment. Observed clinical symptoms, adverse reactions. Treatment of a course of treatment to determine the efficacy. [Result] The treatment group was effective in 24 cases, effective in 10 cases, ineffective in 6 cases, the total effective rate was 85.00%. In the control group, 14 cases were markedly effective, 11 cases were effective, 10 cases were ineffective, and the total effective rate was 71.43%. The treatment group was better than the control group (P <0.05). HBV-DNA negative cases treatment group than the control group (P <0.05). Related indicators improved in both groups (P <0.05), and the treatment group improved better than the control group (P <0.05). [Conclusion] Xuefu Zhuyu Decoction combined with interferon is effective in treating chronic hepatitis B, which is worth promoting.